Press release MHRA approves GLP –one receptor agonist semaglutide to lower possibility of serious coronary heart difficulties in obese or overweight adults Semaglutide is the first weight loss drug authorised in the united kingdom for a preventative cure for all those with set up cardiovascular diseaseThough copyright would be the most widely rec